FDA Sets Regulatory Review Period for Pfizer's Neurontin Patent Extension

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for Pfizer's patent extension application for Neurontin, a medication used to treat epilepsy and nerve pain, in accordance with the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA).